Alloy Therapeutics Partners with Biogen on Multi-Target Collaboration

The deal allows Biogen to leverage Alloy's antibody discovery platform for new drug development.

Apr. 7, 2026 at 12:03pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a glass beaker, metal pipette, and minimalist white laboratory dish, arranged elegantly on a clean, monochromatic grey background to symbolize the abstract concepts of scientific discovery and pharmaceutical innovation.A conceptual still life that captures the innovative spirit behind the Alloy Therapeutics and Biogen collaboration in the field of antibody drug discovery.Boston Today

Alloy Therapeutics, a Boston-based biotechnology company, has entered into a multi-target collaboration and license agreement with pharmaceutical giant Biogen. The deal will enable Biogen to utilize Alloy's proprietary antibody discovery platform to identify and develop new drug candidates across multiple therapeutic areas.

Why it matters

This partnership represents a significant validation of Alloy's technology and expertise in the highly competitive field of antibody drug discovery. It also provides Alloy with an opportunity to expand the reach and impact of its platform through a collaboration with an established industry leader like Biogen.

The details

Under the terms of the agreement, Biogen will have the ability to select multiple targets and leverage Alloy's suite of technologies, including its transgenic animal platforms and in vitro antibody discovery capabilities, to identify and develop new antibody-based therapeutics. Alloy will receive an upfront payment, as well as potential milestone payments and royalties on any products that are successfully developed and commercialized through the collaboration.

  • The agreement was announced on April 7, 2026.

The players

Alloy Therapeutics

A Boston-based biotechnology company that specializes in the development of novel antibody-based therapeutics using its proprietary discovery platform.

Biogen

A leading global biopharmaceutical company that develops and commercializes innovative therapies for the treatment of neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with Biogen and leverage our cutting-edge antibody discovery platform to help advance their pipeline of innovative therapies.”

— Errik Anderson, CEO of Alloy Therapeutics

“This collaboration with Alloy Therapeutics aligns with our strategy to access novel technologies and expand our capabilities in antibody drug discovery.”

— Michel Vounatsos, CEO of Biogen

What’s next

The companies expect to initiate the first target selection and research activities under the collaboration in the coming months.

The takeaway

This partnership between Alloy Therapeutics and Biogen demonstrates the growing importance of innovative biotechnology companies in driving the development of new therapeutic options, particularly in the field of antibody-based drugs.